Guyer William's Form 4 filing
Corcept Therapeutics Inc (CORT) · filed Aug 12, 2026
- Accession no.
- 0001193125-26-346942
- Filed
- Aug 12, 2026, 4:26 PM ET
- Trade date
- Aug 10, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.85M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Guyer WilliamCIK 0001879013 | Officer (Chief Development Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | Common Stock | MOption exerciseAcquired | +16,300 | $21.65 | +$352,895 | 20,285 | Direct | |
| Aug 10, 2026 | Common Stock | SSaleDisposed | −11,530 | $113.18F3 | −$1,304,933.12 | 8,755 | Direct | |
| Aug 10, 2026 | Common Stock | SSaleDisposed | −4,770 | $114.04F4 | −$543,956.97 | 3,985 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | Common Stock | MOption exerciseDisposed | −16,300 | $0.00 | $0 | 110,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.80 to $113.75 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F4
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $113.98 to $114.24 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
Remarks
The power of attorney under which this form was signed is on file with the Commission.